Search Results - life+sciences+%3e+therapeutics

242 Results Sort By:
MEK7 inhibitors for acute lymphoblastic leukemia (ALL) treatment
NU 2023-060 INVENTORS Karl Scheidt* Dalton Kim Meghan Orr SHORT DESCRIPTION Rational design of highly potent and selective covalent MEK7 inhibitors BACKGROUND Acute lymphoblastic leukemia (ALL) is a deadly blood cancer, the most common hematological malignancy in patients under 14 years of age. Despite advancements in treatment, ALL relapse...
Published: 8/10/2026   |   Updated: 8/10/2026   |   Inventor(s):  
Keywords(s): ALL - Acute Lymphoblastic Leukemia, Cancer/Oncology, Leukemia, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Covalent MEK4 Inhibitors for Targeted Cancer Therapy
NU 2025-154 INVENTORS Karl Scheidt* Gina Connors SHORT DESCRIPTION This technology introduces novel covalent inhibitors of MEK4, built upon previously-developed reversible inhibitors (see NU2019-059 and NU2021-217). A covalent inhibition strategy offers enhanced potency, selectivity, and prolonged duration of action compared to reversible...
Published: 8/10/2026   |   Updated: 8/10/2026   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Covalent Inhibition, Kinase Inhibitor, Leukemia, MEK4, MEK7, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Improved MEK4 Inhibitors for the Treatment of Cancer
NU 2021-217 INVENTORS Karl Scheidt* Ada Jade Kwong Hidayatullah Munshi Thao Nguyen Pham SHORT DESCRIPTION This technology introduces novel indazole derivatives as potent and selective MEK4 inhibitors for cancer treatment, particularly in advanced prostate cancer and pancreatic adenocarcinoma. The lead molecule is optimized over first-generation...
Published: 8/10/2026   |   Updated: 8/10/2026   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Pancreatic cancer, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
3-Arylindazoles as Selective MEK4 Inhibitors
NU 2019-059 INVENTORS Karl Scheidt* Matthew Clutter Ada Jade Kwong Gary Schiltz SHORT DESCRIPTION This technology discloses novel 3-arylindazole compounds as highly potent and selective MEK4 inhibitors for treating various cancers, including metastatic prostate cancer. The compounds offer promise both as clinical agents and valuable chemical...
Published: 8/10/2026   |   Updated: 8/10/2026   |   Inventor(s):  
Keywords(s):  
Category(s): Life Sciences > Therapeutics
Biopanned peptides targeting glial phenotypes in ramified, primed, and activated brain microglia and astrocytes
NU 2022-114 SHORT DESCRIPTION Northwestern and University of Alberta researchers have developed a phage display selection method that identifies peptides binding microglia and astrocytes according to their inflammatory activation state, along with 58 peptide ligands discovered and validated using it. BACKGROUND Neuroinflammation is a shared component...
Published: 8/6/2026   |   Updated: 8/6/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Biomarker, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Enabling technology, Foreign body response, Implantable devices, Inflammation, Neurodegenerative disease, Neurologic disease
Category(s): Life Sciences > Therapeutics, Life Sciences, Life Sciences > Biomarkers & Biomedical Research Tools
Biradial Spherical Nucleic Acids
Biradial Spherical Nucleic Acids for Targeted and Protected Oligonucleotide Delivery SHORT DESCRIPTION A liposome-based spherical nucleic acid platform that encapsulated oligonucleotides and supports targeted cellular uptake through multivalent, receptor-binding outer oligonucleotides. Prepared using a non-enzymatic manufacturing method, these SNAs...
Published: 8/5/2026   |   Updated: 8/5/2026   |   Inventor(s):  
Keywords(s):  
Category(s): Life Sciences > Therapeutics
CD40L-targeted therapies for myeloid diseases
NU 2016-012 INVENTORS Peng Ji* Kehan Ren Ermin Li SHORT DESCRIPTION Methods of targeting CD40L for treating TET2-mutant pre-malignant myeloid conditions BACKGROUND TET2 is one of the most frequently mutated genes in myeloid neoplasms and their precursor conditions, such as clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia...
Published: 8/3/2026   |   Updated: 8/3/2026   |   Inventor(s):  
Keywords(s): AML - Acute myeloid leukemia, Cancer Treatment, Cancer/Oncology, Immunotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
CD73-PROTACs for Cancer Therapy
SHORT DESCRIPTION A novel first-in-class proteolysis targeting chimera (PROTAC) that selectively degrades CD73 to reverse tumor immune evasion and inhibit cancer progression. INVENTORS Bin Zhang* Northwestern University Feinberg School of Medicine, Department of Medicine (Hematology & Oncology) Gary Schiltz* Weinberg...
Published: 7/6/2026   |   Updated: 7/6/2026   |   Inventor(s):  
Keywords(s): BIO2026, Breast cancer, Cancer/Oncology, Colon cancer, Lung cancer, Melanoma, PROTAC, Targeted therapy, Therapeutics, TPD - Targeted protein degradation
Category(s): Life Sciences > Therapeutics
Non-Invasive Molecular Diagnostic Platform for Multiple Sclerosis
SHORT DESCRIPTION A non-invasive blood biomarker technology that analyzes plasma cfDNA methylation to diagnose multiple sclerosis, classify its subtypes, and predict disease progression. INVENTORS Yaping Liu* (Northwestern University) Zongqi Xia* (University of Pittsburgh) * Principal Investigator NU Tech ID NU...
Published: 6/30/2026   |   Updated: 6/30/2026   |   Inventor(s):  
Keywords(s):  
Category(s): Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Therapeutics, Life Sciences > Healthcare Devices, Tools & IT
Polycomb Repressive Complex 1 (PRC1) Inhibitors to Restore Immune Response in B-Cell Lymphomas
SHORT DESCRIPTION A therapeutic approach that restores MHC-II expression using PRC1 inhibitors to reactivate anti-tumor immunity in B-cell lymphomas. INVENTORS Lu Wang* Zibo Zhao * Principal Investigator NU Tech ID: NU 2025-010 IP STATUS U.S. Provisional Patent Application has been filed. THERAPEUTICS...
Published: 6/25/2026   |   Updated: 6/23/2026   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Immunotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...